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Abstract
Background: Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently
with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with
trastuzumab alone.
Case presentation: We report the case of a 49 year-old woman affected by metastatic breast cancer who
developed trastuzumab-related cardiogenic shock due to pump failure (with LVEF of about 15%) after three months
of treatment. After a long hospitalization in the cardiac intensive care unit and a proper treatment, LVEF increased
to 50% and, due to a severe progression of disease, trastuzumab was resumed and continued for more than one
year.
Conclusion: This is a case of particularly severe cardiotoxicity related to trastuzumab treatment, which was
recovered with pharmacological treatment and the temporary discontinuation of the treatment. Trastuzumab was
safely resumed after clinical and echocardiographic parameters improvement.
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Background
Trastuzumab is a humanized monoclonal antibody that
links the extracellular domain of the HER-2 protein
(HER-2/neu or erbB2) overexpressed in about 20% to
25% of breast cancers. This antibody mediates signaling
pathways leading to increased proliferation. It is ap-
proved for the treatment of early and metastatic breast
cancer [1–3]. In HER-2 positive breast cancer, trastuzu-
mab administered concurrently with chemotherapy has
deeply modified the natural history of the disease by sig-
nificantly improving response rates and survival in pa-
tients receiving chemotherapy and trastuzumab
(CT + TR) compared to those receiving chemotherapy
alone (CT) (median survival 25.1 months in CT + TR
group versus 20.3 months in CT group, P 0.046) [3].
However, trastuzumab use has been found to be asso-
ciated with an high incidence of cardiotoxicity which
varies in the available literature from 0.6% to 4.5% reach-
ing up to 34% when associated with anthracyclines [4].
The pathogenesis of trastuzumab-associated cardiac
function decrease is still unknown and its mechanism of
action is under investigation in small clinical studies.
Several trials have described potential risk factors such
as age, weight and high body mass index (BMI), history
of coronary artery disease and hypertension, cumulative
doxorubicin dose, HER2 expression level, previous treat-
ment, radiation of the chest and negative hormonal re-
ceptor status [5]. However, among these, only age and
concomitant doxorubicin therapy result to correlate with
an increased risk of cardiotoxicity [3]. Moreover, despite
the publication of clinical guidelines for the management
of trastuzumab-induced cardiomyopathy, the choice to
resume trastuzumab therapy after a decline in left ven-
tricular ejection fraction remains a clinical decision
based on expected risks and benefits.
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Here we report the case of a metastatic breast cancer
patient treated with trastuzumab associated to chemother-
apy. She developed extremely severe congestive heart fail-
ure requiring complex specialized treatment. After full
resolution of symptoms and left- ventricle ejection frac-
tion (LVEF) recovery with appropriate therapy, she re-
sumed, because of disease progression, trastuzumab
treatment without any further cardiologic complications.
Few similar cases have been reported in the scientific
literature but this case report is particularly interesting
because the patient never received anthracyclines and,
after resumption, trastuzumab was continued for about
two years without LVEF alterations, resulting in
complete remission of visceral neoplastic disease.
Case presentation
In December 2000, a 49 year-old woman underwent left
mastectomy for a stage IIA invasive ductal breast carcin-
oma with low proliferative activity (Ki 67 < 5%), negative
hormone receptors and HER2 overexpressed (score 3+
at immunochemistry). In her medical history there were
no cardiovascular comorbidities and she had no family
history of cardiovascular disease.
From February to July 2001 she received an adjuvant
chemotherapy with cyclophosphamide 600 mg/sqm,
methotrexate 40 mg/sqm and 5-fluorouracyl 600 mg/
sqm days 1,8. Subsequent follow-up was negative until
September 2005 when a local left axillary relapse was
resected. Histological and biological features of the re-
lapse did not change. Surgical resection was followed,
from January to February 2006, by radiation therapy on
the left chest wall (5000 cGy with fractioned dose of
200 cGy/day). In November 2010, a PET-CT scan was
performed to test for progressive increase in serum bio-
markers. It showed multiple secondary localizations:
lymph-nodal metastases (left axillary, mediastinic, iliac
and lombo-aortic), liver metastases (third segment), and
bone lesions (left seventh rib and left femur acetabu-
lum). Liver biopsy confirmed hormone receptors nega-
tivity and HER2 overexpression (score 3+). The patient
was absolutely asymptomatic (ECOG 0). A screening
echocardiogram (January 2011) found no pathological
findings and a normal left ventricular ejection fraction
(LVEF 64%). At that point, first line chemotherapy with
weekly paclitaxel (80 mg/sqm) associated with weekly
trastuzumab (loading dose of 4 mg/kg followed by main-
tenance dose of 2 mg/Kg) was initiated and paclitaxel
was withdrawn at the second administration because of
hypersensitivity reaction and replaced with docetaxel
(100 mg/sqm every three weeks). A supportive therapy
with bisphophonates (zoledronic acid 4 mg i.v. every
28 days) was also administered for bone metastases. In
March 2011, after three months of treatment (fourteen
administrations of weekly trastuzumab), the patient
referred asthenia, tachycardia, increasing dyspnea for
mild efforts and palpitations. Within few days clinical
conditions rapidly worsened and the patient was admit-
ted to the emergency room for cardiogenic shock (heart
rate 150 beats per minute, blood pressure 70/50 mmHg,
severe oliguria, pulmonary congestion, NYHA 4, AHA
D). An angio-CT scan excluded a pulmonary thrombo-
embolism and the patient was admitted to a cardiac in-
tensive care unit where an echocardiogram revealed a
severe global biventricular dilatation and dysfunction
(LVEF about 15%). Despite a maximal supportive ther-
apy with inotropic agents and diuretics, shock persisted.
Therefore an intraortic balloon pump was implanted
with a very slow but progressive hemodynamic improve-
ment and a resumption of diuresis. In absence of previ-
ous clinical experiences or data from the literature
describing of similar serious clinical presentation using
trastuzumab alone (without current or previous history
of anthracyclines exposure), a myocardium biopsy was
performed finding inflammatory areas of uncertain eti-
ology but not compatible with a myocarditis. After ap-
proximately two months of hospitalization the patient
was progressively weaned by inotropic agents and infu-
sional diuretic therapy, and a heart failure pharmaco-
logical treatment was orally introduced (bisoprolol
2,5 mg, enalapril 2,5 mg, ivabradine 15 mg, canreonate
50 mg, furosemide 100 mg). After four months and with
a slow pharmacological up-titration, we observed a pro-
gressive clinical improvement and an increase and
stabilization of biventricular function (LVEF 45% on
September 2011). In May 2012, a PET-CT scan showed
lymph-nodal, liver and skeletal disease progression, at
which point a second line chemotherapy with vinorel-
bine (25 mg/sqm, days 1,8) was initiated. In July 2012,
after two cycles of chemotherapy, a further tumor as-
sessment documented visceral disease progression.
Therefore, with awareness of the high risk due to recent
severe cardiogenic shock and after discussion with the
patient and her family, we decided to resume trastuzu-
mab therapy along with cardiac therapy. Weekly trastu-
zumab (2 mg/kg) was resumed with a clinical and
echocardiographic cardiac monitoring. Soon thereafter,
radiological evaluations (PET-CT scan and total body
CT scan) showed a partial response of visceral disease.
Trastuzumab and vinorelbine therapy was continued
until June 2013 when, considering the positive response
and the appearance of grade 2 neuropathy, vinorelbine
was interrupted and trastuzumab was continued every
21 days (6 mg/Kg) until April 2014 with no further signs
or symptoms of heart failure. External beam radiother-
apy on left ileo-pubic branch (March 2012, 30 Gy) and
on the second cervical vertebra (January 2013, 2000 cGy
for 5 fractions) were performed for palliative purpose.
Zoledronic acid every 28 days was continued during the
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whole period. Serial echocardiograms performed during
trastuzumab treatment did not reveal LVEF drop main-
taining in the range of 50–55%.
In January 2014 the patient presented diplopia, left eye
squint, postural instability and leg weakness. A CT scan
and MRI (February 2014) revealed the presence of four
cerebral and cerebellar lesions (right cerebellar tonsil,
left frontal and parietal lobe, quadrigeminal plate). The
patient underwent stereotactic gamma-knife radiosur-
gery on February 2014 followed by whole brain irradi-
ation for suspected leptomeningeal involvement
(3000 cGy for 12 fractions). In April 2014 trastuzumab
was interrupted and a new line of chemotherapy with
capecitabine 3000 mg/day (1–14 every 21 days) associ-
ated with tyrosine kinase inhibitor (TKI) lapatinib
250 mg 4 tb/day was started. Subsequent radiological as-
sessment (August 2015) documented a complete remis-
sion of lymph-nodal and liver neoplastic disease and
radiologic stability of bone metastases.
In November 2014 the patient was hospitalized for
acute renal failure secondary to dehydration, fainting
and recurrent vomiting. After discharge, she complained
of severe asthenia, anorexia and weight loss. Conse-
quently, chemotherapy with capecitabine was suspended
and lapatinib was continued as monotherapy for about a
year during which she never reported cough, dyspnea,
chest pain and other symptoms suggestive of heart fail-
ure (NYHA II, AHA C). In November 2015, echocardio-
graphic examination showed no relevant changes
compared to the previous ones. We found an interesting
pattern of LVEF trend along with trastuzumab treatment
– discontinuation – and resumption (Fig. 1).
Over the following three months, the patient experi-
enced a rapid deterioration of general clinical conditions,
with progressive and definitive bedrest and altered
conscience, suggesting a meningeal disease progression.
In January 2016, the last ultrasound examination showed
a progressive liver disease. The patient died on February
24, 2016 from neoplastic disease progression.
Discussion
In this case report we described the case of a patient
treated with trastuzumab who developed a severe con-
gestive heart failure during treatment and who resumed
trastuzumab therapy after proper cardiac management
and left ventricular ejection fraction recovery.
Similarly to our case, Castells and colleagues reported
the case of a breast cancer patient who developed a se-
vere heart failure (LVEF 23%) after adjuvant treatment
with doxorubicin and trastuzumab. Her cardiac function
improved after positioning of a left ventricular axial
pump. She fully recovered after 135 days of support
therapy and the axial pump was successfully removed
[6]. Conversely to our experience this patient did not
need any further trastuzumab treatment.
The literature includes three cases similar to our ex-
perience. In the first report Hermann and colleagues de-
scribed two breast cancer patients who had received
trastuzumab monotherapy and were hospitalized for a
rapidly worsening heart failure following hypertensive
crisis, in one case due to the interruption of antihyper-
tensive drugs and in the other case to an underlying
sclerodermia. In both cases trastuzumab therapy was
safely resumed after adequate treatment of the under-
lying causes of the heart failure [7].
Martin and colleagues reported on a patient with a left
ventricular ejection fraction drop from 76% to 55% dur-
ing adjuvant sequential anthracycline-containing chemo-
therapy followed by trastuzumab-based therapy; ejection
fraction was restored after starting therapy with the
Fig. 1 Left ventricular ejection fraction values in the treatment period. T: trastuzumab, D: docetaxel, VNR: vinorelbine, C: capecitabine, L: lapatinib
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ACE-inhibitor captopril, and trastuzumab was resumed
without complications [8].
Unlike anthracycline-induced cardiotoxicity, trastuzu-
mab cardiotoxicity has some peculiar features: 1) the
risk does not seem to be dose related [9]; 2) there is no
evidence that cardiac damage is associated with ultra-
structural changes in myocytes and 3) it is fully revers-
ible after treatment suspension [10]. Acute congestive
heart failure due to anthracycline-induced cardiotoxicity
is often serious and require a long-term hospitalization
with a multidisciplinary approach. In contrast,
trastuzumab-related cardiotoxicity is less severe and at
least partially reversible in many cases [3].
Cardiotoxicity occurs more frequently in patients with
preexisting hypertension and obesity, former or current
smokers, with cardiologic comorbidities and with a fam-
ily history of cardiovascular disease. Our patient had no
cardiological comorbidities, she had not received
anthracycline-based therapies although radiation therapy
on the left chest wall was performed five years before.
Tumor hormonal receptors, another risk factor, were
also negative.
Typically, there is a rapid improvement in clinical con-
ditions and ejection fraction after trastuzumab discon-
tinuation and standard treatment allowing resumption
of trastuzumab, as we did for our patient.
In the present report our patient developed cardio-
genic shock due to a severe biventricular dysfunction
probably caused by trastuzumab four months after the
beginning of the treatment. One year later, after a full re-
covery from heart failure, because of disease progression,
and with consideration of the clinical benefits from anti-
HER2 treatment and the absence of absolute cardiologic
contraindications (LVEF was significantly improved with
proper treatment), therapy with full dose trastuzumab
was resumed along with a close monitoring program of
left ventricular function for about two years without any
further cardiovascular complications. In summary, our
patient completed a line of chemotherapy with trastuzu-
mab. Subsequently, we performed 12 cycles with trastu-
zumab (6 mg/Kg) alone which led to a complete
remission of visceral disease.
The question of how best to prevent trastuzumab-
related cardiotoxicity continues to be debated. Since the
exposure to both trastuzumab and an anthracycline
leads to the greatest risk, guidelines recommend avoid-
ing concurrent exposure to these two agents. Another
strategy could be to identify patients who are at greater
risk of cardiac complications from trastuzumab therapy
by using a radiolabeled trastuzumab (111In-DTPA-tras-
tuzumab) and by evaluating scintigraphic myocardial up-
take [11]. Other than a study by Cardinale et al., there is
little data from the literature on the utility of cardiac
biomarkers for trastuzumab, such as TnI [12]. Increase
of TnI was found exclusively in patients pre-treated with
anthracyclines and in seven patients was reported prior
to trastuzumab exposure, suggesting possible additional
effects on a previous anthracycline-induced myocyte
injury.
Although this is only a single case-report we believe it
to be valuable because the cardiac function of our pa-
tient recovered, despite the severity of heart failure with-
out a previous exposure to anthracyclines, following
adequate cardiac management, allowing her to benefit
from prolonged trastuzumab treatment followed by add-
itional anti-HER2 agent lapatinib treatment.
Conclusions
Trastuzumab can lead to a severe cardiac toxicity, in-
cluding in patients never previously exposed to anthra-
cyclines and irrespective of other risk factors. It is
usually reversible and, when recognized early, responds
to the discontinuation of the antibody and to standard
heart failure treatment, providing the opportunity for re-
sumption of therapy if necessary.
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